Condition
Type 2 Diabetes
Cardiovascular Risk
Locations
United States
Start date
24/08/2026
Identifiers
Trial ID NN9490-8665,
NCT number NCT07797335,
Eudract number Not Available
NCT number NCT07797335,
Eudract number Not Available
Summary
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.
Trial Overview:
Treatment
DRUG: Zenagamtide
DRUG: Insulin glargine U-100
Study type
INTERVENTIONAL
Trial duration
Aug 24 2026 - Sep 20 2028
Participants
1778
Phase
III
Are you eligible?
Gender
Male and female
Age
45 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.